Only a small percentage of people with early dementia eligible for new Alzheimers drugs

Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in Neurology. Clinical trial results for these drugs are only available in people in the […]
» Read more